Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 2/20 | 0.61 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | USP5 | P45974 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723028 | 1.00 | ACVR1 (0.61) | ACVR1IP6K1KDM4EHPGDHSD17B10 | |
| SCHEMBL29608405 | 0.85 | ACVR1 (0.49) | ACVR1IP6K1KDM4EHPGDHSD17B10 | |
| SCHEMBL6921434 | 0.78 | IP6K1 (0.52) | ACVR1IP6K1KDM4EL3MBTL1 | |
| SCHEMBL3636921 | 0.78 | RAB9A (0.57) | KDM4EHPGDHSD17B10USP5GAA | |
| SCHEMBL19049515 | 0.77 | LMNA (0.61) | RAB9ASMN1; SMN2POLBCYP1A2CYP2D6 | |
| SCHEMBL22021641 | 0.76 | KDM4E (0.54) | KDM4EHPGDHSD17B10USP5GAA | |
| SCHEMBL16181504 | 0.76 | KDM4E (0.54) | KDM4EHPGDHSD17B10USP5GAA | |
| SCHEMBL6972582 | 0.76 | KDM4E (0.54) | KDM4EHPGDHSD17B10USP5GAA | |
| SCHEMBL30743619 | 0.76 | KDM4E (0.54) | KDM4EHPGDHSD17B10USP5L3MBTL1 | |
| SCHEMBL258690 | 0.76 | KDM4E (0.54) | KDM4EHPGDHSD17B10USP5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-10 | — | — | US | claimed |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | claimed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | claimed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-117946012-A | Preparation method of nitrogen-containing heterocycle | 温州理工学院 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2003076438-A1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076395-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076400-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003024450-A1 | METHODS FOR TREATING PRION DISEASES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| CN-1356983-A | Tri-aryl acid derivatives as PPAR receptor ligands | AVENTIS PHARM PROD INC (DE) | 2002-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | TGFB1, TGFBR1, TGFB2 | ACVR1 25/4885IP6K1 324/4885KDM4E 1077/4885 |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | ACVR1 7/4885IP6K1 959/4885KDM4E 1460/4885 |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | ACVR1 7/4885IP6K1 959/4885KDM4E 1460/4885 |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | ACVR1 7/4885IP6K1 959/4885KDM4E 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.